SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile plans to become a wireless carrier have fueled concern that T-Mobile could face greater long-term competition, contributing to a sharp selloff in telecom stocks. Traders are divided between viewing SpaceX as a future threat and calling the reaction excessive because building a competitive terrestrial network would require substantial investment and time.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Discussion centers on Midnights mainnet launch and reported Coinbase listing, with traders also highlighting Google Cloud and Vodafone validator participation as signs of growing reach. Supporters see adoption momentum, while skeptics point to ongoing token-selling pressure and question whether the developments will translate into sustained demand.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs sharp rallies and pullbacks are driving the discussion, with traders citing CME futures access and a Grayscale filing as possible catalysts for an earlier breakout. Bulls point to BCHs relative strength and the planned CashVM upgrade, while skeptics question its utility and warn that momentum could fade.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is being linked to anticipation of founder Patrick Soon-Shiongs Piper Sandler oncology symposium chat, where he is expected to discuss trial progress; traders are also watching for updates on bladder-cancer programs and international expansion. Some bullish posts speculate about a partnership or short squeeze, but those claims remain unverified.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

IOVAs rally is drawing attention amid the companys higher revenue outlook and expectations for upcoming melanoma, sarcoma and lung-cancer updates. Traders also point to a reported decline in short interest as a possible source of buying pressure, while others warn that the sharp run-up could give way to volatility and debate whether the NSCLC update will arrive on schedule.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

RYCEY is drawing attention amid a persistent pullback, with traders debating whether the weakness reflects market and geopolitical pressure or a change in the companys outlook. Long-term bulls point to aerospace and defense demand, Rolls-Royces India engine plans and SMR prospects, while speculation about an unannounced hyperscaler deal remains a recurring source of anticipation and skepticism.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs Buy upgrade, citing Palantirs sovereign-AI and customized-software growth opportunities, is fueling attention alongside a breakout to new highs. Bulls are celebrating the momentum and speculating about a short squeeze, while skeptics argue the valuation is stretched and warn of a pullback.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention amid weak price performance and concerns about exchange delistings, with traders debating whether the listing changes are materially bearish or being overstated. Bulls point to JasmyChain activity and ecosystem developments as potential sources of utility, while critics question whether meaningful adoption has emerged.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas non-binding plan to acquire its first U.S. data center and expand its AI infrastructure footprint is drawing attention. Some traders view the move as strategic growth, while many question how it will be financed and whether the company can execute, with those concerns accompanying the selloff.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Uncertainty over NASAs delayed CLPS 2.0 lunar-contract awards is the main focus, with traders watching for a decision and debating whether Intuitive Machines could benefit. Bulls view a contract as a potential catalyst, while bears point to repeated delays, a persistent downtrend, and weakness across space stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Turning Towards Momentum Narratives

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR

Ernexa Scores Independent Validation Before High-Stakes Human Cancer Therapy Trials

Ernexa Therapeutics (NASDAQ:ERNA) has taken a notable step toward the clinic after announcing that an independent contract research organization successfully reproduced the preclinical efficacy of its lead cell therapy candidate, ERNA-101, in ovarian cancer models. Independent validation is closely watched in biotechnology because reproducibility can strengthen confidence in experimental findings before human testing begins.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million.
Catheter Precision (AMEX:VTAK)read more...

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.

Chasing the Next Explosive Small-Cap Run

Risk appetite came roaring back and several companies standing out, as market participants rotated heavily into sectors tied to transformative technologies and high-growth macro trends. $TGNT, $QUCY, $AEHL, $TDIC, $WGRX, $ERNA, $SLS, $WHWK

Ernexa Stock Is Jumping Today: What's Going On?

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA 101 in ovarian cancer.read more...

ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts 

Equity

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period.

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results

Ernexa’s ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance...

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the research and development of cellular therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. Its pipeline includes ERNA-101 (Ovarian Cancer) and ERNA-201 (Rheumatoid Arthritis). The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$ERNA been a long wait, but feel news is next week. 800k milestone warrants are @ $17. They need to pump this big to get the proceeds.

Brian Thomson

$ERNA it started running up after hours and hit $4.82 and some DIP SHIT, starts putting in lower offer prices at $4.30 and at $4.04 what a fool, I grabbed more at $4.30, I bought at 4.02 right before the close, been holding for a few weeks, got out of it all at $4.95, and bought some back at $4.00 on the drop, thanks fools

$ERNA presenting at HC Wainwright Wed. First time IB has invited them. Exciting times. Perhaps we see a PIPE with legit funds in coming weeks. Would rerate the stock signficantly.

$ERNA soon under 1, just watch. I see 90 cents bids, Sanjeev is looting money with both hands

Russell

$ERNA Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

Day Trader

Follow @ApolloAlerts … One of the best Small-Cap traders out there.  
  
Banked $12K today off of his call!! Big thanks 🙌 
 
Watching $ERNA & $HQ for tomorrow

Ming

$ERNA Disciplined Capital Allocation: Advancing the Nearest Value-Creating Milestones 
 
Following the encouraging ERNA-201 results, Ernexa has elected to pause additional preclinical development expenditures on ERNA-201 at this time and preserve the program while concentrating near-term resources on ERNA-101 and the expansion of its oncology pipeline. 
 
The decision is a capital allocation priority rather than a scientific decision to discontinue ERNA-201. The Company believes the positive preliminary results provide a foundation from which ERNA-201 could potentially be advanced in the future as resources, strategic priorities and development opportunities warrant. 
 
"We have achieved an important objective with ERNA-201 by generating encouraging proof-of-concept data," Luther said. "The question for us now is not whether we believe in the program. We do. The question is where each incremental dollar and each hour of our team's effort can have the greatest impact today.

Feed

News

Sentiment

Fundamentals

Info

ERNA Ernexa Therapeutics Inc.

Fundamentals

Latest ERNA News